Pharmaceutical Cold Chain Sustainability Solutions - How to Improve CO2 Footprint & ROI
November 28, 2022
The pharma sector is a major contributor to global greenhouse gas emissions, with emission intensity being approximately 55 percent higher than that of the automotive sector. Global leaders in the pharmaceutical industry are prioritizing the elimination of harmful greenhouse gas emissions to limit global temperature to the 1.5-degree rise, as proposed in the Paris Climate Agreement of December 2015. The need to improve CO2 footprint in the pharmaceutical cold chain is now more than ever. From ambition to action, Berlinger has turned the challenge of high emissions in cold chain logistics into an opportunity for innovation. The company has developed an entirely new smart monitoring ecosystem “SmartSystem” meeting the various challenges of the industry among others real-time coverage, costs and sustainability. The basis for innovation is a baseline carbon footprint analysis of the Berlinger product portfolio. The project that was successfully completed with the renowned sustainability advisory South Pole in 2021 significantly impacted the innovation process of SmartSystem - in terms of hardware platform and respective business models - and resulted in the awarding of the Climate Neutral Product Label in 2022. In this webinar, Berlinger and South Pole discuss the impact of climate actions on the pharma cold chain market, the Berlinger and South Pole climate journey as well as how sustainability can add value to the respective business case. Berlinger argues that improving the ROI whilst reducing CO2 emissions in the pharmaceutical cold chain are not mutually exclusive.
How do you retain patients in a complex trial? For clinical research professionals, testing medications and procedures on patient populations who feel unwell and have mobility or logistical challenges can be taxing, physically, mentally and emotionally for patients and their families - disruptive to their everyday lives and to the everyday lives of their families. For many clinical trialists, patient retention and engagement, especially in a complex trial, are challenges that keep them up at night, worrying that valuable patients will not complete the trial. A DCT is proven to improve patient retention, but if it’s a method of conducting research that the trialist hasn’t experienced before, the benefit, value and possibilities when building decentralized trial visits into a protocol, might not be fully realized. There are many procedures that can be completed in the home, and a significant number of those are far more complex than anticipated. From double blinded healthcare professionals delivering IMP, to timed pharmacokinetic blood draws and digitally linked visits, there are so many complex visit types that can be delivered in a DCT.
The assurance cookie is found and is being filtered in Google Analytics.
These cookies are used to collect information about how you interact
with our website and allow us to remember you. We use this
information in order to improve and customize your browsing
experience, and for analytics and metrics about our visitors both on
this website and other media. To find out more about the cookies we
use, see our